Search ARM

GelMEDIX is a preclinical stage regenerative medicine company developing a hydrogel platform for improving cell and gene therapy delivery. Our lead program is an allogenic iPSC-derived retinal pigment epithelial (RPE) cell therapy with an in situ forming hydrogel formulation to treat Geographic Atrophy.

Contact GelMEDIX, Inc.
Visit Website